top of page
Home
Solutions
Treatment Selection
LiquidHALLMARK®
Screening & Health Risk Assessment
CardioHemeRISK™
Treatment Selection
LiquidHALLMARK®
Screening & Health Risk Assessment
CardioHemeRISK™
Communities
Oncologists
Patients
Insurers
Investors
Oncologists
Patients
Insurers
Investors
Knowledge Center
Publications
News & Updates
Webinars
Case Studies
Publications
News & Updates
Webinars
Case Studies
Patient Stories
About Us
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
Mobile menu (US)
Portal Login
Close
Home
Solutions
Screening and Health Risk Assessment
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Treatment Selection
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Hereditary Risk Assessment
Lumi Series
Treat Response Monitoring
LucenceMONITOR™
Screening and Health Risk Assessment
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Treatment Selection
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Hereditary Risk Assessment
Lumi Series
Treat Response Monitoring
LucenceMONITOR™
Communities
Primary Care Doctors
Oncologists
Patients
Investors
Primary Care Doctors
Oncologists
Patients
Investors
Knowledge Center
Publications
News & Updates
Webinars
Case Studies
Patient Stories
Publications
News & Updates
Webinars
Case Studies
Patient Stories
About Lucence
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
Mobile menu (RoW)
Close
Solutions
Screening & Health Risk Assessment
LucenceINSIGHT®
CardioHemeRISK™
LucenceLONGEVITY™
Menu
Close
Treatment Selection
LiquidHALLMARK® & LiquidMARK™
LiquidSCREEN™ Lung
HemeMARK™
UNITED™ 600
UNITED™ CNS
Rapid TissueMARK™
NPC GOLD™
Menu
Close
Hereditary Risk Assessment
Lumi Series
Menu
Close
Treatment Response Monitoring
LucenceMONITOR™
Menu
Close
Treatment Selection
LiquidHALLMARK®
Menu
Close
Communities
Communities
Oncologists
Patients
Insurers
Investors
Menu
Close
Communities
Primary Care Doctors
Oncologists
Patients
Investors
Menu
Close
Knowledge Center
Knowledge Center
Publications
News & Updates
Webinars
Case Studies
Patient Stories
Menu
Close
About Us
About Us
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
Menu
Close
Menu
Close
Solutions
Screening and Health Risk Assessment
CardioHemeRISK™
Menu
Close
Treatment Selection
LiquidHALLMARK®
Menu
Close
Communities
Communities
Oncologists
Patients
Insurers
Investors
Menu
Close
Knowledge Center
Knowledge Center
Publications
News & Updates
Webinars
Case Studies
Patient Stories
Menu
Close
About Us
About Us
About Lucence
Leadership
Medical Advisory Board (Coming Soon)
Careers
Contact Us
Menu
Close
Menu
Close
Portal Login
News & Updates
Filter by:
Select Year
News & Updates
20 Nov 2019
Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid Biopsy for Early Detection of Multiple Cancers
Read More
Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid Biopsy for Early Detection of Multiple Cancers
Go
Go
1
/
5
Go
Go
Like
bottom of page
